Impax Laboratories Inc

Impax Laboratories — Q1 2016 Earnings Presentation

23 slides from Impax Laboratories's earnings presentation, May 10, 2016

  1. Slide 1: 10, 2016

    10, 2016

  2. Slide 2: Cautionary Statement Regarding Forward Looking Statements

    Impax Cautionary Statement Regarding Forward Looking Statements safe Harbor” statement under the Private Securities Litigation Reform Act of 1995; To the extent any statements made in this presentation contain information that is not historical; these statements are forward-looking in nature and exp

  3. Slide 3: Agenda

    Agenda Fred Wilkinson + 1Q 2016 Highlights President & CEO + Update on Key Areas of Focus Bryan Reasons SVP & CFO + 1Q 2016 Financial Review Executive Team

  4. Slide 4: Highlights & Update

    Highlights & Update Fred Wilkinson President & Chief Executive Officer

  5. Slide 5: Quarterly Highlights

    Quarterly Highlights Revenues Adjusted EBITDA Adjusted Diluted EPS $ millions $ millions $225.5 ane. $143.1 $083. $24.0 = 1015 1016 1015 1016 1015 1016 "Generic » Specialty Pharma + Offto a solid start in 2016 + Reaffirmed 2016 financial outlook + Initiated supply chain and cost efficiency initiativ

  6. Slide 6: Focusing on Quality and Operations

    Focusing on Quality and Operations Restructuring Supply Chain to Reduce Costs, Improve Operating Efficiencies and Enhance Long Term Competitive Position * Closing Middlesex, NJ manufacturing and packaging facility through course of next two years Transferring products and functions: » Impax’s Haywar

  7. Slide 7: Maximizing Generic Platform

    Maximizing Generic Platform Targeted Launches Current U.S. Brand/Generic market sales of $1B 6 to8 oF 6 t H Approved Not Yet Pending FDA Launched or Re- Approval introduction Source of sales data: I'S March 2016; Data as of ay 9, 2016; “Assuming receipt offal FD Progress of Targeted Launches | Produ

  8. Slide 8: Multiple Generic Opportunities to Drive Future Growth

    Multiple Generic Opportunities to Drive Future Growth 21 Products Pending at FDA 23 Products Under Development Current U.S. Brand/Generic Market - $7B Current U.S. Brand/Generic Market - $12B 24% Potential/Confirmed FTF or FTM 61% Potential FTF or FTM I Solid Oral Dosage [ll] Alternative Dosage Form

  9. Slide 9: Maximizing Specialty Pharma Platform

    Maximizing Specialty Pharma Platform In First Quarter 2016 ree ited Expansion of Sale: + Builds scale to support organic growth + Provides increased frequency and geographic reach + Expands from 77 sales reps to approximately 120 + Recruitment initiated in 1Q16 and sales force expansion currently ex

  10. Slide 10: Rytary: Choose, Improve, Ease Access

    Choose Rytary Improve Customer Experience Ease Access 1200 10000 | ow | 00 | en | °! + Increase frequency of visits and geographic reach with expanded sales force + Increase prescriber use for an earlier e Parkinson's disease patient wearing “off’ onimmediate release pa levodopa + Enhancing educatio

  11. Slide 11: Maximizing Specialty Pharma Platform: Targeting Prolific Physicians

    Maximizing Specialty Pharma Platform Targeting the Most Prolific Physicians + Pinworm is a highly contagious parasite that infects approximately 40 million people in the U.S. each year* + Increase awareness that Mebendazole is back - the only FDA approved prescription therapy + Recapture the Pinworm

  12. Slide 12: 2016 Priorities

    2016 Priorities Focus on Quality and Operations + Maintain quality and compliance across all facilities / departments + Sharpen focus on supply chain and costefficiencies + Improve conversion costs across global manufacturing network Maximize Dual Platform + Optimize existing generic opportunities +

  13. Slide 13: Financial Review

    Financial Review Bryan Reasons Senior Vice President & Chief Financial Officer

  14. Slide 14: 1Q 2016 Financial Summary

    1Q 2016 Financial Summary $ millions, except per share amounts 10 2016 10 2015 Total Revenues $2255 $143.1 57.6% Adjusted Gross Margin 50.1% 474% 2Tppts Adjusted SG&A Expense $43.5 $40.4 71% Adjusted R&D Expense $187 $15.0 24.7% Adjusted EBITDA $63.6 $24.0 165.0% Adjusted Diluted EPS $0.43 $0.09 377

  15. Slide 15: 1Q 2016 Segment Performance

    1Q 2016 Segment Performance except are amounts 1Q 2016 1Q 2015 thange GENERIC DIVISION Total Revenues $170.4 $1287 32.2% Adjusted Gross Margin 39.3% 45.0% (87)ppts Adjusted Operating Income $47.6 $42.0 13.3% SPECIALTY PHARMA DIVISION Total Revenues $55.4 $14.4 284.7% Adjusted Gross Margin 83.5% 68.8

  16. Slide 16: Well-Positioned Capital Structure

    Well-Positioned Capital Structure Significant Financial Resources and Flexibility to Support Growth Capitalization as of March 31, 2016 Leverage ($ millions) Net Debt $ 188 Cash and Cash Equivalents $412 LTM Adjusted EBITDA $ 265 Net Debt / Adjusted EBITDA 0.7x Revolver ($100) $ 0 2022 Convertible S

  17. Slide 17: Q&A

  18. Slide 18: Appendix

    Appendix

  19. Slide 19: GAAP to Adjusted Net Income Reconciliation

    GAAP to Adjusted Net Income Reconciliation The following table reconciles reported net loss to adjusted net income. (Unaudited, amounts in thousands, except per share and per share data) ‘Three months ended March 31, 2016 2015 Net loss $ (10,408) “S$ (6,333) Adjusted to add (deduct): ‘Amortization 8

  20. Slide 20: GAAP to Adjusted Results Reconciliation

    GAAP to Adjusted Results Reconciliation ‘The following table reconciles total Company reported cost of revenues, research and development expenses, and selling, general and administrative expenses to adjusted cost of revenues, adjusted gross profit, adjusted gross margin, adjusted research and devel

  21. Slide 21: GAAP to Adjusted EBITDA Reconciliation

    GAAP to Adjusted EBITDA Reconciliation The following table reconciles reported net loss to adjusted EBITDA. (Unaudited, amounts in thousands) Three months ended March 31, 2016 2015 Net loss $ (10.408) “$ (6.333) Adjusted to add (deduct): Interest income 333) (284) Interest expense 8,331 3,975 Deprec

  22. Slide 22: Generic Division GAAP to Adjusted Results Reconciliation

    Generic Division GAAP to Adjusted Results Reconciliation ‘The following tables reconcile the Impax Generics Division reported cost of revenues to adjusted cost of revenues, adjusted gross Proft, adjusted gross margin and adjusted operating income. (Unaudited, amounts in thousands) ‘Three months ende

  23. Slide 23: Specialty Pharma Division GAAP to Adjusted Results Reconciliation

    Specialty Pharma Division GAAP to Adjusted Results Reconciliation The following tables reconcile the Impax Spec ity Pharma Divisions reported cost of revenues to adjusted cost of revenues, adjusted gross profit, adjusted gross margin and adjusted operating income (Unaudited, amounts in thousands) ‘T

Impax Laboratories — Q1 2016 Earnings Presentation on 6ix